Kelly D. Foote

Kelly D. Foote

Auto-generated profile, based on publicly available information

Kelly D. Foote

University of Florida

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JSJavier Simón-Sánchez
Javier Simón-Sánchez
CSClaudia Schulte
Claudia Schulte
JBJose M Bras
Jose M Bras
MSManu Sharma
Manu Sharma
JGJ Raphael Gibbs
J Raphael Gibbs
TGThomas Gasser
Thomas Gasser
Andrew Singleton, Thomas Gasser and colleagues report results of a genome-wide association study of Parkinson's disease among individuals of European ancestry. They find genome-wide significant associations at two loci, SNCA and MAPT, and provide supporting evidence for a new risk locus on 1q32. We performed a genome-wide association study (GWAS) in 1,713 individuals of European ancestry with Parkinson's disease (PD) and 3,978 controls. After replication in 3,361 cases and 4,573 controls, we observed two strong association signals, one in the gene encoding α-synuclein (SNCA; rs2736990, OR = 1.23, P = 2.24 × 10−16) and another at the MAPT locus (rs393152, OR = 0.77, P = 1.95 × 10−16). We exchanged data with colleagues performing a GWAS in Japanese PD cases. Association to PD at SNCA was replicated in the Japanese GWAS1, confirming this as a major risk locus across populations. We replicated the effect of a new locus detected in the Japanese cohort (PARK16, rs823128, OR = 0.66, P = 7.29 × 10−8) and provide supporting evidence that common variation around LRRK2 modulates risk for PD (rs1491923, OR = 1.14, P = 1.55 × 10−5). These data demonstrate an unequivocal role for common genetic variants in the etiology of typical PD and suggest population-specific genetic heterogeneity in this disease.

1 February 2011 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
JBJeff Bronstein
Jeff Bronstein
MTMichele Tagliati
Michele Tagliati
RARon L. Alterman
Ron L. Alterman
ALAndres M Lozano
Andres M Lozano
JVJens Volkmann
Jens Volkmann
MDMahlon R. DeLong
Mahlon R. DeLong
Surgical treatment of Parkinson disease (PD) was described as early as 1940 and, until recently, had focused on ablative procedures of the thalamus and globus pallidus pars interna (GPi). These surgical treatments (especially pallidotomy) rose to prominence in the era before levodopa (LD) but later reemerged as popular approaches in the 1990s. They were rapidly replaced in the late 1990s by deep brain stimulation (DBS), mainly as a result of concerns for adverse effects resulting from bilateral lesions as well as the irreversible effects resulting from poorly placed lesions. Furthermore, a new target, the subthalamic nuclei (STN) was identified to be an effective target and quickly became the most common site for DBS electrode placement.1-3

20 May 2008 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
BGB D Greenberg
B D Greenberg
LGL A Gabriels
L A Gabriels
DMD A Malone
D A Malone
ARA R Rezai
A R Rezai
GFG M Friehs
G M Friehs
BNB J Nuttin
B J Nuttin
Psychiatric neurosurgery teams in the United States and Europe have studied deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) for severe and highly treatment-resistant obsessive-compulsive disorder. Four groups have collaborated most closely, in small-scale studies, over the past 8 years. First to begin was Leuven/Antwerp, followed by Butler Hospital/Brown Medical School, the Cleveland Clinic and most recently the University of Florida. These centers used comparable patient selection criteria and surgical targeting. Targeting, but not selection, evolved during this period. Here, we present combined long-term results of those studies, which reveal clinically significant symptom reductions and functional improvement in about two-thirds of patients. DBS was well tolerated overall and adverse effects were overwhelmingly transient. Results generally improved for patients implanted more recently, suggesting a ‘learning curve’ both within and across centers. This is well known from the development of DBS for movement disorders. The main factor accounting for these gains appears to be the refinement of the implantation site. Initially, an anterior–posterior location based on anterior capsulotomy lesions was used. In an attempt to improve results, more posterior sites were investigated resulting in the current target, at the junction of the anterior capsule, anterior commissure and posterior ventral striatum. Clinical results suggest that neural networks relevant to therapeutic improvement might be modulated more effectively at a more posterior target. Taken together, these data show that the procedure can be successfully implemented by dedicated interdisciplinary teams, and support its therapeutic promise.

13 March 2009 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MOMichael S. Okun
Michael S. Okun
HFHubert H. Fernandez
Hubert H. Fernandez
SWSamuel S. Wu
Samuel S. Wu
LKLindsey Kirsch‐Darrow
Lindsey Kirsch‐Darrow
DBDawn Bowers
Dawn Bowers
KFKelly D. Foote
Kelly D. Foote

1 August 2005 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
MOMichael S. Okun
Michael S. Okun
MTMichele Tagliati
Michele Tagliati
MPMichael Pourfar
Michael Pourfar
HFHubert H. Fernandez
Hubert H. Fernandez
RRRamon L. Rodriguez
Ramon L. Rodriguez
KFKelly D. Foote
Kelly D. Foote
Research from JAMA Neurology — Management of Referred Deep Brain Stimulation Failures — A Retrospective Analysis From 2 Movement Disorders Centers

1 February 2012 in The Lancet Neurology
Verified
Journal Article
Closed access
MOMichael S Okun
Michael S Okun
BGBruno V Gallo
Bruno V Gallo
GMGeorge Mandybur
George Mandybur
JJJonathan Jagid
Jonathan Jagid
KFKelly D Foote
Kelly D Foote
MTMichele Tagliati
Michele Tagliati